IOV-4001
Phase 2Biologic
IOV-4001 is one of 46 biologic programs targeting Metastatic Melanoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Metastatic Melanoma
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbApproved
Keytruda
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Fludara
SanofiPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rifadin
SanofiApproved
Imbruvica
PPharmacyclics LLC.
Approved
Mektovi
PfizerPhase 3
Braftovi
PfizerPhase 3
Farydak
SSecuraBio
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IOV-4001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- IIovance Biotherapeutics, Inc.